For the quarter ending 2026-03-31, XRAY had -$136M decrease in cash & cash equivalents over the period. -$12M in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -10 | -145 | -428 | -44 |
| Depreciation | 38 | 37 | 36 | 34 |
| Amortization of intangible assets | 41 | 56 | 56 | 54 |
| Goodwill impairment | - | 116 | 253 | 156 |
| Intangible asset impairment | - | 37 | 9 | 79 |
| Deferred income taxes | -60 | -14 | 180 | -137 |
| Stock-based compensation expense | 8 | 8 | 6 | 9 |
| Other non-cash (income) expense | 15 | 23 | 6 | -10 |
| Loss (gain) on disposal of property, plant and equipment | - | 0 | - | - |
| Gain on disposal of assets | 6 | - | - | - |
| Accounts and notes receivable-trade, net | -60 | 35 | 25 | 0 |
| Inventories, net | 23 | -44 | 14 | 21 |
| Prepaid expenses and other current assets | -19 | -3 | 36 | -27 |
| Other noncurrent assets | -1 | 7 | 1 | 3 |
| Accounts payable | 2 | 20 | 1 | -24 |
| Accrued liabilities | -20 | -8 | -31 | 9 |
| Income taxes | 7 | 13 | 10 | -43 |
| Other noncurrent liabilities | -2 | -1 | 69 | -58 |
| Net cash provided by operating activities | 40 | 101 | 79 | 48 |
| Cash received on sale of non-strategic businesses or product lines | - | 0 | - | - |
| Capital expenditures | 52 | 41 | 39 | 32 |
| Cash received on derivative contracts | - | 0 | 9 | 0 |
| Net investment hedge settlements | 7 | 5 | 7 | 2 |
| Proceeds from sale of property, plant, and equipment | - | - | - | 0 |
| Other investing activities | -6 | -1 | -2 | - |
| Net cash used in investing activities | -53 | -45 | -36 | -34 |
| Cash paid for treasury stock | - | 0 | 0 | 0 |
| Proceeds from 364-day bridge loan | 0 | 0 | 0 | 0 |
| Repayment of 364-day bridge loan | - | 0 | 0 | 435 |
| Repayments on short-term borrowings | -51 | 80 | -3 | -141 |
| Cash dividends paid | 32 | 32 | 32 | 32 |
| Proceeds from long-term borrowings | - | 2 | 1 | 550 |
| Repayments on long-term borrowings | 31 | 144 | 1 | 0 |
| Cash paid for deferred financing costs | 0 | 3 | 0 | 10 |
| Other financing activities, net | -5 | -2 | -1 | 0 |
| Net cash (used in) provided by financing activities | -119 | -99 | -36 | -68 |
| Effect of exchange rate changes on cash and cash equivalents | -4 | 6 | -3 | 15 |
| Net (decrease) increase in cash and cash equivalents | -136 | -37 | 4 | -39 |
| Cash and cash equivalents at beginning of period | 326 | 363 | 359 | 398 |
| Cash and cash equivalents at end of period | 190 | 326 | 363 | 359 |
DENTSPLY SIRONA Inc. (XRAY)
DENTSPLY SIRONA Inc. (XRAY)